Research programme: stem cell targeting therapeutics - Celprogen

Drug Profile

Research programme: stem cell targeting therapeutics - Celprogen

Alternative Names: CEP 1205; CEP 1206; CEP 1207; CEP 1430; CEP 1507; CEP 3007; CEP 3009; CEP 3061; CEP 3095; CEP 4002; CEP 4021; CEP 5003; STEM 5007; STEMC 7007; STEMC5007

Latest Information Update: 26 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Celprogen
  • Class Small molecules
  • Mechanism of Action Glucagon receptor agonists; Glucose transporter type 1 stimulants; Hedgehog cell-signalling pathway inhibitors; Insulin growth factor agonists; Somatostatin modulators; Stem cell modulators; Stem cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Brain cancer; Breast cancer; Colorectal cancer; Diabetes mellitus; Liver cancer; Lung cancer; Malignant melanoma; Ovarian cancer; Pancreatic cancer; Stem cell mobilisation

Most Recent Events

  • 16 Apr 2016 Pharmacodynamics data from a preclinical study in Pancreatic cancer presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016)
  • 13 Apr 2016 Research programme: stem cell targeting therapeutics - Celprogen is available for licensing as of 13 Apr 2016.
  • 11 May 2015 Preclinical trials in Diabetes mellitus in USA (PO, IV, IM, Intraperitoneal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top